Nurix Therapeutics (NRIX) Current Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has 6 years of Current Leases data on file, last reported at $3.2 million in Q2 2026.

• On a quarterly basis, Current Leases fell 38.47% year-over-year to $3.2 million in Q2 2026; TTM through May 2026 was $3.2 million, a 38.47% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 64.76% from the prior year.
• Current Leases for Q2 2026 stood at $3.2 million, up from $3.2 million in the prior quarter.
• Over the last five years, Current Leases for NRIX reached as high as $8.0 million in Q4 2024 and fell as low as $2.8 million in Q4 2025.
• Historically, Current Leases has averaged $5.6 million across 5 years, with a median of $5.5 million in 2022.
• Across the five-year window, Current Leases surged 43.75% in 2022 and sank 64.76% in 2025, its largest moves.
• Year by year, Current Leases stood at $5.5 million in 2022, then surged by 35.42% to $7.5 million in 2023, then increased by 7.01% to $8.0 million in 2024, then sank by 64.76% to $2.8 million in 2025, then grew by 14.06% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $3.2 million in Q2 2026, $3.2 million in Q1 2026, and $2.8 million in Q4 2025.